- Remarks on biomarkers of cardiovascular risk2018 | Third Faculty of Medicine
- Some of the myths of contemporary lipidology2015 | First Faculty of Medicine
- The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation2019 | First Faculty of Medicine
- The PROMINENT trial - what has it given and taken from us?2023 | First Faculty of Medicine
- Current treatment options for patients with dyslipidemia and cardiometabolic syndrome2015 | Faculty of Medicine in Pilsen
- The role of fibrates in current dyslipidemia therapy2015 | Faculty of Medicine in Pilsen
- Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy2022 | First Faculty of Medicine